Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.25

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $20.25.

NEO has been the topic of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. Benchmark reaffirmed a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research report on Tuesday, September 24th.

NeoGenomics Stock Up 1.1 %

Shares of NEO stock opened at $18.01 on Friday. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22. The stock has a market cap of $2.31 billion, a PE ratio of -29.52 and a beta of 1.24. The business’s fifty day moving average is $14.89 and its 200-day moving average is $14.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The company had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. During the same period last year, the firm earned ($0.06) EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Equities analysts expect that NeoGenomics will post -0.17 earnings per share for the current fiscal year.

Insider Activity at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of NeoGenomics by 1.6% during the 3rd quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock worth $73,139,000 after acquiring an additional 80,449 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 14.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after acquiring an additional 480,396 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after acquiring an additional 217,687 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of NeoGenomics by 5.4% during the 2nd quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock worth $45,241,000 after acquiring an additional 167,145 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of NeoGenomics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after acquiring an additional 36,136 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.